Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been given a consensus rating of “Hold” by the five research firms that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $3.33.

Several equities research analysts have recently commented on the stock. HC Wainwright restated a “neutral” rating and issued a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. StockNews.com assumed coverage on shares of Syros Pharmaceuticals in a report on Tuesday. They issued a “sell” rating for the company. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th.

Institutional Investors Weigh In On Syros Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SYRS. Two Sigma Securities LLC purchased a new stake in Syros Pharmaceuticals during the fourth quarter valued at approximately $25,000. GSA Capital Partners LLP purchased a new stake in Syros Pharmaceuticals during the third quarter valued at approximately $34,000. Finally, Exome Asset Management LLC lifted its position in Syros Pharmaceuticals by 87.6% during the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after acquiring an additional 139,400 shares during the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Stock Performance

NASDAQ:SYRS opened at $0.16 on Friday. Syros Pharmaceuticals has a one year low of $0.15 and a one year high of $7.96. The firm has a market cap of $4.21 million, a P/E ratio of -0.05 and a beta of 1.30. The firm has a 50-day simple moving average of $0.20 and a 200-day simple moving average of $1.10.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.